The current cost-of-living crisis – defined by the soaring cost of essential services – is not the result of excessive consumer demand or short-term inflation shocks. It is the product of decades of trade and industrial policy choices that weakened middle-class wage growth.
China’s foray into the automotive industry makes perfect sense for any serious, powerful economy. Every major economic power has its own car brands. China has them now, in droves.
The U.S. goods deficit with China fell by roughly $2 billion in September, coming in at $15.03 billion. China has dropped to fourth place in terms of the countries in which the U.S. has its biggest goods gap.
A proposed 807-mile natural gas pipeline intended to bring gas from Alaska’s North Slope to a new export terminal in the Kenai Peninsula in Southcentral Alaska will be fabricated in Korea despite the Administration’s headline “fifty percent” steel tariff.
Democrats on the House Committee on Small Business kept to their year-long messaging that tariffs are raising costs and hurting companies. There were many interesting themes from the Nov. 20 hearing titled How Main Street is Revitalizing Domestic Manufacturing.
The affordability crisis is primarily a result of price increases in five major sectors of consumer spending: housing, food, health care, child care, and energy. In none of those sectors are tariffs a significant factor.
To trade away aluminum and steel workers’ home market in exchange for padding Big Tech’s bottom line overseas is immoral and wrong. The Section 232 actions on aluminum and steel should be singularly focused on rebuilding domestic output across the supply chains, not used as leverage to help Google and Meta become even more profitable.
The America First Investment Policy rightly seeks to ensure that Wall Street can no longer channel hundreds of billions of U.S. dollars into companies that build China’s military, commit human rights atrocities, and threaten our national security. CPA strongly supports Chairman Moolenaar’s effort to codify this policy into law.
The Senate Special Committee on Aging was back at it this week discussing the woeful predicament of the domestic generic drug industry and its import-facing supply chain. This time, the Committee heard from four generic drug makers opposed to advocacy groups and Washington think tanks.
The Commerce Department should look to 7 C.F.R. Part 6 as a terrific example of how USDA has ensured that quota allocation benefits domestic manufacturers, not speculators.
